Bifogade filer
20250821_PM_Isofol_Invitation webcast Q2 2025
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, August 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors, analysts and media to a webcast presentation and Q&A session in connection with the company publishing its interim report for the second quarter on August 26.
In connection with the publication of the interim report for the second quarter of 2025, Isofol invites investors, analysts and media to a webcast presentation on August 26, at 11:00 a.m. The presentation will be held by Isofol’s CEO Petter Segelman Lindqvist and CFO Margareta Hagman, summarising recent progress and the company’s financial position, followed by a question and answer session. The presentation will be held in English.
Date and time
August 26, 2025, at 11:00 a.m.
Link to webcast
If you wish to participate online and send written questions, connect via the link below:
https://www.finwire.tv/webcast/isofol-medical/q2-2025/
For more information, please contact
Isofol Medical AB
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0) 738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CEST, on August 21, 2025.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.